NFKB1 and breast carcinoma: Liquiritin inhibits the NF-κB signaling pathway in MDA-MB-231 and MCF-7 cells, reduces System Xc- expression, promotes ferroptosis, and alleviates resistance of breast cancer tissue to doxorubicin (111).